{"id":"bupropion-lozenge","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Insomnia"},{"rate":"10-20","effect":"Dry mouth"},{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Hiccups (lozenge-related)"},{"rate":"5-10","effect":"Mouth irritation (lozenge-related)"}]},"_chembl":{"chemblId":"CHEMBL1201735","moleculeType":"Small molecule","molecularWeight":"320.66"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bupropion is an atypical antidepressant that blocks reuptake of norepinephrine and dopamine, reducing the rewarding effects of nicotine and decreasing cravings. The nicotine lozenge provides transdermal nicotine replacement to manage acute withdrawal symptoms. This combination approach addresses both the neurochemical basis of addiction and acute withdrawal discomfort.","oneSentence":"Bupropion inhibits norepinephrine and dopamine reuptake to reduce nicotine cravings, while the lozenge delivers nicotine to ease withdrawal symptoms during smoking cessation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:41:18.315Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Smoking cessation"}]},"trialDetails":[{"nctId":"NCT04604509","phase":"PHASE4","title":"Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-04","conditions":"Cigarette Smoking-Related Carcinoma","enrollment":2010},{"nctId":"NCT04694846","phase":"NA","title":"Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2020-08-19","conditions":"Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma","enrollment":19},{"nctId":"NCT03670316","phase":"PHASE4","title":"Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2020-08-17","conditions":"HIV, AIDS, Smoking Cessation","enrollment":378},{"nctId":"NCT05351606","phase":"PHASE4","title":"Integrating Tobacco Use Cessation Into HIV Care and Treatment in Kisumu County, Kenya","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2023-05-16","conditions":"Tobacco Use Cessation, Tobacco Use","enrollment":580},{"nctId":"NCT04717544","phase":"NA","title":"Embedding Comprehensive Smoking Cessation Programs Into Community Clinics","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2019-10-01","conditions":"Smoking Cessation","enrollment":406},{"nctId":"NCT04135937","phase":"PHASE4","title":"Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2019-11-18","conditions":"Human Immunodeficiency Virus, Smoking","enrollment":12},{"nctId":"NCT02245308","phase":"PHASE4","title":"Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2014-10-01","conditions":"Tobacco Use Disorder, Homelessness","enrollment":133},{"nctId":"NCT02050308","phase":"PHASE3","title":"Web-based Smoking Cessation Program for Tribal College Students","status":"COMPLETED","sponsor":"Won Choi, PhD, MPH","startDate":"2015-05","conditions":"Smoking Cessation","enrollment":251},{"nctId":"NCT02995915","phase":"PHASE4","title":"Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-11","conditions":"Smoking Cessation, Alcohol Drinking","enrollment":45},{"nctId":"NCT04501016","phase":"PHASE2, PHASE3","title":"A Stepped Care Approach to Treating Tobacco Use in Rural Veterans","status":"NOT_YET_RECRUITING","sponsor":"Iowa City Veterans Affairs Medical Center","startDate":"2020-09","conditions":"Tobacco Cessation","enrollment":100},{"nctId":"NCT02869451","phase":"NA","title":"Mobile Contingency Management for Marijuana and Tobacco Cessation","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-08","conditions":"Cigarette Smoking, Marijuana Abuse","enrollment":7},{"nctId":"NCT01871506","phase":"NA","title":"Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2013-09","conditions":"Smoking Cessation","enrollment":303},{"nctId":"NCT01592695","phase":"PHASE2","title":"Tailored Tobacco Quitline for Rural Veterans","status":"COMPLETED","sponsor":"Iowa City Veterans Affairs Medical Center","startDate":"2012-06","conditions":"Cigarette Smoking","enrollment":63},{"nctId":"NCT02994082","phase":"NA","title":"Treating Smokeless Tobacco Use in Rural Veterans","status":"UNKNOWN","sponsor":"Mark Vander Weg","startDate":"2016-12","conditions":"Smokeless Tobacco, Nicotine Dependence","enrollment":123},{"nctId":"NCT02420015","phase":"PHASE4","title":"Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-03-27","conditions":"Schizophrenia, Cigarette Smoking","enrollment":35},{"nctId":"NCT01901848","phase":"PHASE2, PHASE3","title":"CPT and Smoking Cessation","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2013-12-11","conditions":"Stress Disorders, Post-Traumatic, Smoking","enrollment":69},{"nctId":"NCT02873754","phase":"NA","title":"Smoking Treatment and Exercise Program for Underserved Populations (STEP UP)","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-01","conditions":"Smoking","enrollment":11},{"nctId":"NCT01892813","phase":"PHASE3","title":"Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers","status":"UNKNOWN","sponsor":"Mark Vander Weg","startDate":"2013-07","conditions":"Nicotine Dependence, Tobacco Use","enrollment":411},{"nctId":"NCT00320697","phase":"PHASE4","title":"Smoking Relapse Prevention in Schizophrenia","status":"COMPLETED","sponsor":"North Suffolk Mental Health Association","startDate":"2006-04","conditions":"Schizophrenia, Schizoaffective Disorder, Smokers","enrollment":25},{"nctId":"NCT00296647","phase":"PHASE4","title":"Smoking Cessation Intervention: Effectiveness in Primary Care","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2004-09","conditions":"Tobacco Dependence","enrollment":1346},{"nctId":"NCT01990079","phase":"NA","title":"Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD","status":"COMPLETED","sponsor":"Duke University","startDate":"2013-12","conditions":"PTSD, Smoking","enrollment":15},{"nctId":"NCT01789710","phase":"NA","title":"Contingency Management for Smoking Cessation in Homeless Smokers","status":"COMPLETED","sponsor":"Duke University","startDate":"2013-01","conditions":"Smoking, Homeless Persons","enrollment":25},{"nctId":"NCT01576640","phase":"PHASE4","title":"Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2005-12","conditions":"Nicotine Dependence, Schizophrenia","enrollment":17},{"nctId":"NCT01309217","phase":"PHASE4","title":"Dissemination of Tobacco Tactics for Hospitalized Smokers","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2011-07","conditions":"Smoking Cessation","enrollment":1528},{"nctId":"NCT00332644","phase":"PHASE4","title":"Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2004-09","conditions":"Nicotine Dependence","enrollment":1504}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":55,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"bupropion + lozenge","genericName":"bupropion + lozenge","companyName":"University of Wisconsin, Madison","companyId":"university-of-wisconsin-madison","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bupropion is a small molecule that inhibits the sodium-dependent dopamine transporter, a mechanism that may contribute to its therapeutic effects. It has been studied as a treatment for various conditions, including cigarette smoking, marijuana abuse, schizophrenia, and schizoaffective disorder, among others.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}